Clinical Trials Logo

Lymphoma, Mantle-cell clinical trials

View clinical trials related to Lymphoma, Mantle-cell.

Filter by:

NCT ID: NCT03579888 Terminated - Clinical trials for Recurrent Mantle Cell Lymphoma

CD19-Specific T Cells Post AlloSCT

Start date: June 26, 2020
Phase: Phase 1
Study type: Interventional

This phase I trial investigates the side effects and best dose of CD19 positive (+) specific CAR-T cells in treating patients with CD19+ lymphoid malignancies, such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, small lymphocytic lymphoma, or chronic lymphocytic lymphoma. Sometimes researchers change the genetic material in the cells of a patient's T cells using a process called gene transfer. Researchers then inject the changed T-cells into the patient's body. Receiving the T-cell infusion may help to control the disease.

NCT ID: NCT03571828 Terminated - Clinical trials for Follicular Lymphoma (FL)

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma

Start date: October 29, 2018
Phase: Phase 1
Study type: Interventional

Evaluate the safety and tolerability of AMG 562 in adult subjects with DLBCL, MCL, or FL. Estimate the maximum tolerated dose (MTD) and/or a biologically active dose (e.g., recommended phase 2 dose [RP2D])

NCT ID: NCT03567876 Active, not recruiting - Clinical trials for Lymphoma, Mantle-Cell

Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL

Start date: September 3, 2018
Phase: Phase 2
Study type: Interventional

Prospective, multicenter, phase II trial designed to evaluate whether the addition of Venetoclax after rituximab, bendamustine and cytarabine (R-BAC) to high risk patients with mantle cell lymphoma improves the results of the standard R-BAC, in terms of Progression Free Survival.

NCT ID: NCT03547115 Recruiting - Clinical trials for Acute Myeloid Leukemia (AML)

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

Start date: May 31, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies or voruciclib in combination with venetoclax in subjects with relapsed or refractory AML

NCT ID: NCT03523975 Active, not recruiting - Clinical trials for Mantle Cell Lymphoma

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

Start date: December 24, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine if giving an experimental drug called venetoclax in combination with lenalidomide and rituximab is safe and effective for treating people with Mantle Cell Lymphoma (MCL).

NCT ID: NCT03505944 Active, not recruiting - Clinical trials for Relapsed Non Hodgkin Lymphoma

Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma

VALERIA
Start date: July 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I/II trial, with the aim of evaluating the efficacy of venetoclax to the backbone of rituximab-lenalidomide in patients with relapsed/refractory MCL.

NCT ID: NCT03501576 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

Start date: April 6, 2018
Phase:
Study type: Observational

This clinical trial evaluates the influenza virus vaccination in evaluating human immune response in patients with lymphoma. Evaluating immune response may increase the understanding of how the immune system changes when patients receive treatment for lymphomas by looking at the antibody levels and the level of the different cells that make up the immune system over time compared to those without lymphoma.

NCT ID: NCT03494179 Active, not recruiting - Clinical trials for Mantle Cell Lymphoma

A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)

Start date: April 2, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The phase I/II clinical study is to investigate the safety, tolerability and pharmacokinetics/ pharmacodynamics of ICP-022.

NCT ID: NCT03479268 Active, not recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

Start date: March 22, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of pevonedistat when given together with ibrutinib in participants with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has come back or has stopped responding to other treatments. Pevonedistat and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03478514 Active, not recruiting - Clinical trials for Mantle Cell Lymphoma

Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

Start date: September 11, 2018
Phase: Phase 2
Study type: Interventional

The proposed study is a single-arm, multi-center, open-label phase II study of the combination of palbociclib and ibrutinib in patients with previously treated mantle cell lymphoma to evaluate the efficacy of this combination, with the primary objective of the study being to assess median PFS and the secondary objectives to include ORR, CR, DOR, OS and toxicity. Subjects will be enrolled and treated with palbociclib and ibrutinib with each cycle of therapy being 28 days. Treatment will be based on the recommended phase II dose (RP2D) from the phase I combination trial.